Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?

Teva Pharmaceutical shares have jumped about 45% after beating third-quarter expectations, but the company still carries substantial debt, a history of operating losses, hasn't paid a dividend, and now trades at a rich P/E near 50—pricing in significant upside. By contrast, branded rivals Pfizer and Merck are more financially robust with materially lower leverage, consistent profitability and much cheaper valuations (P/E ~15 and ~13), are actively rebuilding pipelines (Pfizer via a GLP‑1 acquisition and partnership; Merck via its Cidara purchase for an influenza candidate), and offer income (Merck ≈3.5% yield, ~45% payout ratio; Pfizer ≈6.7% yield but a concerning ~100% payout ratio). For long-term investors the piece argues Pfizer and Merck may present lower-risk, better-valued opportunities than a rapidly re-rated Teva, which now looks expensive despite momentum.

Analysis

Teva Pharmaceutical rallied roughly 45% in about a month after reporting third-quarter results that beat Wall Street expectations on both revenue and earnings, and the company is positioning itself as a leader in generics while pushing into complex-to-produce generics and branded products. That rapid repricing reflects strong investor enthusiasm but also suggests much positive news is already baked into the stock.

Fundamental cautions remain: Teva carries substantial debt, has a history of operating losses, has not paid a dividend for years, and currently trades at a price-to-earnings ratio just under 50, which contrasts with Pfizer and Merck trading at ~15 and ~13 respectively and exhibiting materially lower leverage and consistent profitability. The valuation divergence highlights higher downside sensitivity for Teva if execution or margin improvement disappoints.

Pfizer and Merck are actively rebuilding pipelines — Pfizer via an acquisition and a GLP-1 partnership, Merck via the Cidara deal for an influenza candidate — and provide income (Merck ~3.5% yield with an approximate 45% payout ratio; Pfizer ~6.7% yield but a roughly 100% payout ratio). For investors with multi-year horizons the article argues Pfizer and Merck offer a lower-risk, better-valued way to access pharmaceutical exposure compared with a fast-rerated Teva.

Key Decisions for Investors

• Avoid initiating new large long positions in TEVA after its ~45% run and P/E near 50; wait for clear evidence of sustained deleveraging, consistent profits, or dividend reinstatement before adding materially to exposure
• Consider allocating new or incremental long exposure to MRK and PFE for multi-year pharmaceutical exposure given lower valuations (P/E ~13 and ~15), stronger profitability and active pipeline rebuilding
• Prefer Merck for income-focused exposure due to the ~3.5% yield and ~45% payout ratio; treat Pfizer's ~6.7% yield with caution because of the ~100% payout ratio risk
• Monitor near-term catalysts closely: Teva debt-reduction progress and sustained EPS trends, Pfizer and Merck clinical readouts and integration of recent acquisitions (GLP-1 activity and Cidara), and patent-expiration timelines that could alter competitive dynamics